Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.
To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Thromboxane b2
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Abdullah NA and Assem ES | Ischaemia and mediator release: interrelationship in antigen-challenged sensitized guinea-pig kidney. | 1990 | Agents Actions | pmid:1695424 |
Ghanem NS et al. | The cardiac and renal effects of the complement fragment C5a des Arg are partly mediated by the release of histamine and arachidonic acid metabolites. | 1989 | Agents Actions | pmid:2473617 |
Lesch ME et al. | The effects of (R)-N-(1-methyl-2-phenylethyl) adenosine (L-PIA), a standard A1-selective adenosine agonist on rat acute models of inflammation and neutrophil function. | 1991 | Agents Actions | pmid:1838897 |
Zatta A et al. | At low extracellular calcium concentration platelet activating factor induces beta-thromboglobulin release from human platelets through thromboxane-endoperoxides formation. | 1987 | Agents Actions | pmid:2961218 |
Carr DP et al. | Comparison of the systemic inhibition of thromboxane synthesis, anti-inflammatory activity and gastro-intestinal toxicity of non-steroidal anti-inflammatory drugs in the rat. | 1986 | Agents Actions | pmid:3825757 |
Conti P et al. | Augmentation of thromboxane production in vitro by polymorphonuclears and macrophages exposed to IL1/LP. | 1986 | Agents Actions | pmid:3485895 |
Srivastava R et al. | Prostanoid mediated effects of centchroman, a non-steroidal oral contraceptive. | 1986 | Agents Actions | pmid:3532722 |
Hoult JR et al. | Failure of anti-inflammatory steroids to inhibit prostaglandin release from the hydronephrotic rabbit kidney. | 1986 | Agents Actions | pmid:3962772 |
Atzori L et al. | Vasoconstriction and bronchoconstriction induced by 2,5-di-(tert-butyl)1,4-benzohydroquinone, an endoplasmic reticular Ca2+-ATPase inhibitor, in isolated and perfused rat lung. | 1992 | Agents Actions | pmid:1414686 |
Ghanem NS and Assem ES | Comparison of the release of various mediators from atrial and ventricular tissues of sensitized guinea-pig hearts. | 1987 | Agents Actions | pmid:2440280 |
de Clerck F et al. | Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist. | 1982 | Agents Actions | pmid:6215842 |
Nosál R et al. | Antihistaminic drug bromadryl and stimulated platelet aggregation. | 1994 | Agents Actions | pmid:7976789 |
de Clerck F et al. | Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41,468), a selective 5-HT2-receptor antagonist. 1982. | 1994 | Agents Actions | pmid:7725978 |
De Clerck F et al. | Platelet activation by endogenous 5-hydroxytryptamine and histamine released by mast cell degranulation with compound 48/80 in the rat. | 1983 | Agents Actions | pmid:6858790 |
Seitz M et al. | The influence of synovial fluid from patients with rheumatoid arthritis on the proliferation of peripheral blood lymphocytes and the prostanoid release from monocytes. | 1981 | Agents Actions | pmid:7340450 |
Prancan A et al. | Platelet thromboxane production during endotoxin shock. | 1981 | Agents Actions | pmid:7340458 |
De Clerck F et al. | Platelet-vessel wall interactions in hemostasis: implication of 5-hydroxytryptamine. | 1984 | Agents Actions | pmid:6543415 |
Ahnfelt-Rønne I et al. | Macrophages from adjuvent arthritic rats preferentially synthetize prostacyclin. | 1980 | Agents Actions | pmid:6992544 |
Patrono C et al. | Inhibition of platelet cyclooxygenase by aspirin-like drugs: methods for in vitro and ex vivo assessment. | 1979 | Agents Actions Suppl. | pmid:115255 |
Patrono C et al. | Radioimmunoassay measurement of stable metabolites of platelet arachidonic acid: a convenient method for the in vitro and ex vivo evaluation of cyclo-oxygenase inhibitors. | 1980 | Agents Actions Suppl. | pmid:6787852 |